0.49
price down icon1.67%   -0.0083
pre-market  Pre-market:  .51   0.02   +4.08%
loading
Lineage Cell Therapeutics Inc stock is traded at $0.49, with a volume of 814.76K. It is down -1.67% in the last 24 hours and down -4.85% over the past month. Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also develops Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV-associated facial lipoatrophy; ReGlyde, a HyStem product in preclinical development as a device for viscosupplementation, and as a platform for intraarticular drug delivery in osteoarthritis; and Premvia, a Hystem Hydrogel product, as well as develop bone grafting products for the orthopedic diseases and injuries. In addition, it markets GeneCards, a human gene database; MalaCards, a human disease database; and Hextend, a plasma volume expander used to treat or prevent hypovolemia, including albumin, generic 6% hetastarch solutions, and crystalloid solutions, as well as undertakes various research programs for vision restoration and Demyelination. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was founded in 1990 and is headquartered in Carlsbad, California.
See More
Previous Close:
$0.4983
Open:
$0.4941
24h Volume:
814.76K
Relative Volume:
0.59
Market Cap:
$91.34M
Revenue:
$8.95M
Net Income/Loss:
$-21.49M
P/E Ratio:
-4.0833
EPS:
-0.12
Net Cash Flow:
$-29.24M
1W Performance:
+19.51%
1M Performance:
-4.85%
6M Performance:
-41.74%
1Y Performance:
-55.86%
1-Day Range:
Value
$0.4647
$0.5138
1-Week Range:
Value
$0.40
$0.5138
52-Week Range:
Value
$0.3651
$1.3999

Lineage Cell Therapeutics Inc Stock (LCTX) Company Profile

Name
Name
Lineage Cell Therapeutics Inc
Name
Phone
510-871-4188
Name
Address
2173 Salk Avenue, Suite 200, Carlsbad, CA
Name
Employee
76
Name
Twitter
@LineageCell
Name
Next Earnings Date
2025-03-10
Name
Latest SEC Filings
Name
LCTX's Discussions on Twitter

Compare LCTX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
LCTX
Lineage Cell Therapeutics Inc
0.49 91.34M 8.95M -21.49M -29.24M -0.12
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
493.84 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
602.64 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
614.76 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
251.56 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
244.90 24.70B 3.81B -644.79M -669.77M -6.24

Lineage Cell Therapeutics Inc Stock (LCTX) Upgrades & Downgrades

Date Action Analyst Rating Change
Aug-20-24 Initiated Craig Hallum Buy
Nov-02-22 Initiated Robert W. Baird Outperform
Jun-14-22 Initiated B. Riley Securities Buy
Aug-19-21 Initiated Noble Capital Markets Outperform
Mar-31-21 Initiated Cantor Fitzgerald Overweight

Lineage Cell Therapeutics Inc Stock (LCTX) Latest News

pulisher
Apr 25, 2025

Lineage Cell Therapeutics Inc [LCTX] Shares Rise 5.57 % on Thursday - knoxdaily.com

Apr 25, 2025
pulisher
Apr 25, 2025

Stem Cell Therapy Market Growth, Trends, & Key Insights | Global - openPR.com

Apr 25, 2025
pulisher
Apr 24, 2025

LCTX’s Stock Market Pendulum: Swinging Between Gains and Losses - investchronicle.com

Apr 24, 2025
pulisher
Apr 22, 2025

Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 3rd Annual Spinal Cord Injury Investor Symposium - BioSpace

Apr 22, 2025
pulisher
Apr 22, 2025

Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 3 - Business Wire

Apr 22, 2025
pulisher
Apr 22, 2025

-2.44 Fall Turns Lineage Cell Therapeutics Inc (LCTX) Into A Losing Stock For Investors - Marketing Sentinel

Apr 22, 2025
pulisher
Apr 21, 2025

Market Recap: Lineage Cell Therapeutics Inc (LCTX)’s Negative Momentum, Closing at 0.41 - DWinneX

Apr 21, 2025
pulisher
Apr 21, 2025

Lineage to Present at 2025 Eyecelerator Meeting Sponsored by the - GuruFocus

Apr 21, 2025
pulisher
Apr 21, 2025

Lineage to Present at 2025 Eyecelerator Meeting Sponsored by the American Academy of Ophthalmology (AAO) - Business Wire

Apr 21, 2025
pulisher
Apr 21, 2025

Revolutionary Eye Drug Delivery Methods: Lineage CEO Joins Elite Panel at Major Ophthalmology Conference - Stock Titan

Apr 21, 2025
pulisher
Apr 17, 2025

Ernexa Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:ERNA - Benzinga

Apr 17, 2025
pulisher
Apr 09, 2025

BioTime, Inc. : CORRECTION - MarketScreener

Apr 09, 2025
pulisher
Apr 09, 2025

BioTime, Inc. : BioTime Announces First Quarter 2012 Financial Results and Recent Corporate Accomplishments - marketscreener.com

Apr 09, 2025
pulisher
Apr 08, 2025

Lineage Cell (LCTX) Reports Q4 Loss, Tops Revenue Estimates - MSN

Apr 08, 2025
pulisher
Apr 08, 2025

BioTime Provides Business Update Including Information on AgeX, OncoCyte and Asterias - MarketScreener

Apr 08, 2025
pulisher
Apr 07, 2025

Let’s Dive Into The Lineage Cell Therapeutics Inc (AMEX: LCTX) Stock Forecast. - Marketing Sentinel

Apr 07, 2025
pulisher
Apr 02, 2025

LCTX Stock: A Comprehensive Analysis and Forecast - investchronicle.com

Apr 02, 2025
pulisher
Apr 01, 2025

Weak Fundamental Momentum Sinks Lineage Cell Therapeutics Inc - Marketing Sentinel

Apr 01, 2025
pulisher
Mar 27, 2025

LCTX stock touches 52-week low at $0.48 amid market challenges - Investing.com

Mar 27, 2025
pulisher
Mar 27, 2025

Lineage Cell Therapeutics : Wave Life Sciences Announces Positive Data from FORWARD 53 Clinical Trial in DMD Including Significant Functional Benefit and Reversal of Muscle Damage after 48 Weeks of Dosing with WVE N531 - MarketScreener

Mar 27, 2025
pulisher
Mar 25, 2025

Cell Therapy Manufacturing Market Demand, Growth and Future - openPR.com

Mar 25, 2025
pulisher
Mar 21, 2025

It’s Worth A Gamble To Have A Position In Lineage Cell Therapeutics Inc (AMEX: LCTX) At $0.50. - Marketing Sentinel

Mar 21, 2025
pulisher
Mar 18, 2025

LCTX stock touches 52-week low at $0.48 amid market challenges By Investing.com - Investing.com South Africa

Mar 18, 2025
pulisher
Mar 18, 2025

Lineage Cell Therapeutics Inc (AMEX: LCTX) Shares Declined By -27.01% In One Month. - Marketing Sentinel

Mar 18, 2025
pulisher
Mar 17, 2025

B. Riley Forecasts Lineage Cell Therapeutics Q1 Earnings - Defense World

Mar 17, 2025
pulisher
Mar 16, 2025

B. Riley Issues Pessimistic Forecast for Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Stock Price - Defense World

Mar 16, 2025
pulisher
Mar 15, 2025

Lineage Cell Therapeutics: 2024 Financial Results and Strategic Progress - TipRanks

Mar 15, 2025
pulisher
Mar 14, 2025

B. Riley Cuts Price Target on Lineage Cell Therapeutics to $3 From $4, Keeps Buy Rating - Marketscreener.com

Mar 14, 2025
pulisher
Mar 14, 2025

HC Wainwright Weighs in on Lineage Cell Therapeutics Q1 Earnings - Defense World

Mar 14, 2025
pulisher
Mar 13, 2025

Now Is The Time To Build A Position In Lineage Cell Therapeutics Inc (AMEX:LCTX) - Marketing Sentinel

Mar 13, 2025
pulisher
Mar 13, 2025

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Receives Buy Rating from D. Boral Capital - Defense World

Mar 13, 2025
pulisher
Mar 12, 2025

Cell Therapy Manufacturing Market Poised for Expansion Biotech - openPR

Mar 12, 2025
pulisher
Mar 12, 2025

Dry AMD Market Expected to rise, 2034 | Alkeus Pharmaceuticals, Belite Bio, Aviceda Therapeutics, Johnson & Johnson Innovative Medicine, Allegro Ophthalmics, Lineage Cell Therapeutics - The Globe and Mail

Mar 12, 2025
pulisher
Mar 12, 2025

Dry AMD Market Expected to rise, 2034 | Alkeus Pharmaceuticals, - openPR

Mar 12, 2025
pulisher
Mar 12, 2025

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Receives “Buy” Rating from HC Wainwright - Defense World

Mar 12, 2025
pulisher
Mar 12, 2025

Lineage Cell Therapeutics stock target cut to $3 by Craig-Hallum - Investing.com Australia

Mar 12, 2025
pulisher
Mar 12, 2025

Lineage Cell Therapeutics Faces Uncertainty Amid New U.S. Administration’s Policies - TipRanks

Mar 12, 2025
pulisher
Mar 11, 2025

Lineage Cell Therapeutics’ Earnings Call: Progress Amid Challenges - TipRanks

Mar 11, 2025
pulisher
Mar 11, 2025

Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 11, 2025
pulisher
Mar 11, 2025

Beyond The Numbers: 7 Analysts Discuss Lineage Cell Therapeutics Stock - Benzinga

Mar 11, 2025
pulisher
Mar 11, 2025

Lineage Cell Therapeutics Inc (LCTX) Q4 2024 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance

Mar 11, 2025
pulisher
Mar 10, 2025

Earnings call transcript: Lineage Cell’s Q4 2024 results show revenue rise By Investing.com - Investing.com South Africa

Mar 10, 2025
pulisher
Mar 10, 2025

Lineage Cell Therapeutics earnings beat by $0.01, revenue topped estimates - Investing.com Canada

Mar 10, 2025
pulisher
Mar 10, 2025

Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - BioSpace

Mar 10, 2025
pulisher
Mar 10, 2025

Earnings call transcript: Lineage Cell’s Q4 2024 results show revenue rise - Investing.com India

Mar 10, 2025
pulisher
Mar 10, 2025

Lineage Cell Therapeutics shares surge 6.8% on positive OpRegen data By Investing.com - Investing.com South Africa

Mar 10, 2025
pulisher
Mar 10, 2025

Lineage Cell Therapeutics shares surge 6.8% on positive OpRegen data - Investing.com

Mar 10, 2025
pulisher
Mar 10, 2025

Lineage Cell Reports Q4 Revenue Growth, FDA Breakthrough Status for Eye Treatment - StockTitan

Mar 10, 2025
pulisher
Mar 07, 2025

Lineage Cell Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire

Mar 07, 2025
pulisher
Mar 07, 2025

How Will Lineage Cell Therapeutics Inc (AMEX: LCTX) Look After It Drops -203.77% From Its Highs? - Marketing Sentinel

Mar 07, 2025
pulisher
Mar 05, 2025

Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on March 10, 2025 - BioSpace

Mar 05, 2025

Lineage Cell Therapeutics Inc Stock (LCTX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$20.59
price up icon 0.24%
$69.69
price up icon 1.06%
$32.20
price up icon 0.53%
$23.46
price down icon 36.06%
$102.02
price down icon 15.36%
biotechnology ONC
$244.90
price down icon 4.40%
Cap:     |  Volume (24h):